HERE IS A LINK THAT EXPLAINS IT IS A 4 TO 6 MONTH DELAY. (( LINK ))
Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes
Sarepta is preparing to submit the dystrophin and clinical outcomes summaries and will be requesting a follow-up meeting with the FDA to discuss these later this quarter. As a result, the End-of-Phase II CMC meeting with the FDA is now expected to occur in the third quarter
Would not change the original timeline a LICK since the manufacturing review wouldn't be complete until then, so NO IMPACT to AA and NO IMPACT to the kids. And per Chris at the Needham Conference they (Sarepta AND the FDA) are working to expedite the process. The source you are citing is old news and has apparently been overtaken by events.